Immunomodulatory effects of RXR rexinoids: Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

Gullu Gorgun, Francine Foss

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression. Exposure to 10-6 to 10-10 M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxicating cells expressing high-affinity IL-2R, These results suggest a rationale for combining rexinoids with IL-2R-targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)1399-1403
Number of pages5
JournalBlood
Volume100
Issue number4
DOIs
StatePublished - Aug 15 2002
Externally publishedYes

Fingerprint

Retinoid X Receptors
Interleukin-2 Receptors
Modulation
B-Cell Leukemia
T-Cell Leukemia
Retinoic Acid Receptors
T-cells
Cells
Cutaneous T-Cell Lymphoma
Hematologic Neoplasms
Autoimmune Diseases
Fusion reactions
Genes
denileukin diftitox
Growth
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Immunomodulatory effects of RXR rexinoids : Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. / Gorgun, Gullu; Foss, Francine.

In: Blood, Vol. 100, No. 4, 15.08.2002, p. 1399-1403.

Research output: Contribution to journalArticle

@article{eedaeae0c4f24909bfa3e4049ae8374e,
title = "Immunomodulatory effects of RXR rexinoids: Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox",
abstract = "Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression. Exposure to 10-6 to 10-10 M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxicating cells expressing high-affinity IL-2R, These results suggest a rationale for combining rexinoids with IL-2R-targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases.",
author = "Gullu Gorgun and Francine Foss",
year = "2002",
month = "8",
day = "15",
doi = "10.1182/blood-2002-01-0300",
language = "English (US)",
volume = "100",
pages = "1399--1403",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Immunomodulatory effects of RXR rexinoids

T2 - Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

AU - Gorgun, Gullu

AU - Foss, Francine

PY - 2002/8/15

Y1 - 2002/8/15

N2 - Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression. Exposure to 10-6 to 10-10 M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxicating cells expressing high-affinity IL-2R, These results suggest a rationale for combining rexinoids with IL-2R-targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases.

AB - Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression. Exposure to 10-6 to 10-10 M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxicating cells expressing high-affinity IL-2R, These results suggest a rationale for combining rexinoids with IL-2R-targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0037103316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037103316&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-01-0300

DO - 10.1182/blood-2002-01-0300

M3 - Article

C2 - 12149223

AN - SCOPUS:0037103316

VL - 100

SP - 1399

EP - 1403

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -